Another interesting characteristic of this genetic predictive signature from a clinical point of view is the recurrence of cancer/testis antigens (CTAs) such as MAGEC2 [49–51], MAGEA12 [52, 53], MAGEA2 [54], and LDHC [55], which are interesting targets for cancer immunotherapy [56] and are consistently under-expressed in CIMP-positive tumors. This evidence concerns the gene LDHC and cancer.